<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MYL</title>
	<atom:link href="http://www.stockbloghub.com/tag/myl/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AZN) US Court Rejects AstraZeneca&#8217;s Case</title>
		<link>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196</link>
		<comments>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196#comments</comments>
		<pubDate>Thu, 19 Apr 2012 20:24:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97196</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) announced that US District Court for the District of Columbia has dismissed the lawsuit filed by the company against the US Food and Drug Administration (FDA). AstraZeneca had taken legal action against the FDA, challenging the agency’s decision to reject AstraZeneca’s Citizen Petitions. The Citizen Petitions were filed by the company for Seroquel (quetiapine fumarate) and Seroquel XR. The Citizen Petitions were filed to bar the FDA from approving any generic versions of the drug that do not include warnings related to hyperglycemia and suicidality in its label. With this move, AstraZeneca was looking to delay the launch of generic versions of Seroquel considering the company has marketing exclusivity for the data associated with the hyperglycemia warning till December 2, 2012. Meanwhile, the UK High Court has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/19/azn-us-court-rejects-astrazenecas-case/97196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players</title>
		<link>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647</link>
		<comments>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:16:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=95647</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson &#38; Johnson (JNJ) company, recently filed a joint lawsuit against several generic companies that are looking to launch their generic versions of Bystolic (nebivolol). The patent infringement lawsuit has been filed in the US District Court for the District of Delaware for infringement of US Patent No. 6,545,040. The lawsuit has been filed against companies like Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories, Inc. (WPI). Another patent infringement lawsuit has been filed by Forest Labs and Janssen in the US District Court for the Northern District of Illinois against Alkem Laboratories Limited and Indchemie Health Specialties Pvt. Ltd. This lawsuit is also related to the infringement of the ‘040 patent. With the lawsuits ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/frx-forest-laboratories-and-janssen-pharmaceutica-sue-generic-players/95647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Earns Positive News on Pipeline</title>
		<link>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441</link>
		<comments>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441#comments</comments>
		<pubDate>Tue, 06 Mar 2012 21:31:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94441</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary endpoint in two phase III studies. The studies were conducted to evaluate cariprazine for the treatment of acute exacerbation of schizophrenia. Results showed that patients in the cariprazine arm achieved a significant improvement in symptom compared to patients in the placebo arm. Statistically significant separation from placebo was observed in all doses from week 2 and at each subsequent time point. Forest Labs and Gedeon said that the higher dose showed separation as early as week 1 of treatment.  The results were similar to data presented earlier from a phase IIb fixed-dose placebo-controlled study. Cariprazine is one of the candidates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire and Sangamo BioSciences Cut a Deal</title>
		<link>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440</link>
		<comments>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:22:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91440</guid>
		<description><![CDATA[Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP”) technology. Terms of the Deal Shire will make an upfront payment of $13 million to Sangamo. Sangamo will also be eligible to receive milestone payments of up to $213.5 million based on the achievement of research, regulatory, development and commercial targets. Shire will pay Sangamo tiered double-digit royalties on product sales. As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048</link>
		<comments>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048#comments</comments>
		<pubDate>Mon, 30 Jan 2012 17:11:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91048</guid>
		<description><![CDATA[Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years. Moreover, we are encouraged by Mylan&#8217;s geographic reach and product depth along with a robust generic product pipeline. We believe the generic segment will post strong sales in 2012 benefiting from a slew of product launches already lined up. We have therefore upgraded our rating on Mylan from Neutral to Outperform to reflect our overall bullish stance for generic makers. Our target price for the stock is $26.00. MYLAN INC (MYL): Free Stock Analysis Report]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Watson Pharmaceuticals Joins Pfizer for Generic Lipitor</title>
		<link>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086</link>
		<comments>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086#comments</comments>
		<pubDate>Tue, 06 Dec 2011 17:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88086</guid>
		<description><![CDATA[November 30, 2011 was a big day for Pfizer, Inc. (PFE) with its blockbuster cholesterol drug, Lipitor, losing exclusivity in the US. With so many drugs losing exclusivity, why is the loss of exclusivity of Lipitor such a major event? Well, Lipitor has been a huge revenue generator and its loss of exclusivity could very well represent the biggest generic opportunity in recent times. Lipitor sales came in at $10.7 billion in 2010 with sales for the first nine months of 2011 coming in at $7.6 billion. Pfizer Goes Aggressive Typically, whenever a branded drug loses exclusivity, it witnesses a rapid erosion in sales with the entry of generic versions. However, Pfizer is trying to turn the tide in its favor by adopting several steps to minimize the impact of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/06/pfe-watson-pharmaceuticals-joins-pfizer-for-generic-lipitor/88086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Approved for Zinecard Generic</title>
		<link>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803</link>
		<comments>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803#comments</comments>
		<pubDate>Thu, 01 Dec 2011 14:57:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87803</guid>
		<description><![CDATA[Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia &#38; Upjohn&#8217;s Zinecard injection. Zinecard injection, which is a chemoprotective agent, recorded revenue of approximately $3.4 million for the trailing twelve months ending in September 2011. As of November 28, 2011, the company had 161 abbreviated new drug applications (ANDAs) that were pending clearance by the FDA, targeting $97.7 billion in branded sales. Mylan believes that about 43 of these ANDAs are first-to-file opportunities, representing more than $26.9 billion in branded sales. Earlier this month Mylan reached a settlement agreement with Novartis (NVS) relating to the generic version of the latter’s bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Novartis</title>
		<link>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474</link>
		<comments>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:41:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87474</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic version of Vivelle-Dot on December 16, 2013, or earlier under certain circumstances. Mylan was the first to file an abbreviated new drug application (ANDA) with the US Food &#38; Drug Administration (FDA) to market the generic version of the drug. Accordingly, Mylan will enjoy an exclusivity period of 180 days when it will be the sole company to market the generic. The deal is subject to review by the US Department of Justice and the Federal Trade Commission. Earlier this month, Mylan entered into an agreement with Pfizer, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Roche for Xeloda</title>
		<link>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911</link>
		<comments>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911#comments</comments>
		<pubDate>Fri, 23 Sep 2011 19:05:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83911</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which is used for the treatment of metastatic breast and colorectal cancers. Xeloda generated revenue of $570 million in the trailing twelve months ending June 30, 2011, according to IMS Health. The details of the agreement have been kept confidential. The agreement will be applicable once it is reviewed by the US Department of Justice and the Federal Trade Commission. Mylan also recently announced that its Indian subsidiary, Matrix, has received tentative approval from the US Food and Drug Administration (FDA) to market a novel ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling</title>
		<link>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359</link>
		<comments>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:57:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MNTA]]></category>
		<category><![CDATA[Momenta Pharmaceuticals Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82359</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement lawsuit against Novartis AG (NVS)/Momenta Pharmaceuticals, Inc. (MNTA) and Mylan Inc. (MYL)/Natco Pharma Ltd. The lawsuit is regarding the company’s lead drug Copaxone, marketed for the treatment of multiple sclerosis (MS). The Court adopted all relevant claim construction interpretations of Teva and rejected all the claim construction interpretations put forth by Novartis/Momenta and Mylan/Natco. Moreover, the Court denied Mylan&#8217;s motion for summary judgment that the disputed patents are invalid for indefiniteness. We note that Teva’s patent for Copaxone is set to expire in 2014. The company has filed a Citizen Petition (CP) with the US Food and Drug Administration ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/teva-teva-pharmaceutical-industries-earns-favorable-court-ruling/82359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823</link>
		<comments>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823#comments</comments>
		<pubDate>Thu, 25 Aug 2011 16:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81823</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents and also beat the year-ago earnings 37 cents. Earnings growth was driven by an increase in generics revenue and improved gross margins. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 17% to $1.44 billion in the second quarter of 2011 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in other markets like Asia-Pacific and North America. Mylan is one of the leading players in the generics market. A large number of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Gets HIV Rights from Gilead</title>
		<link>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031</link>
		<comments>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:42:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79031</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access to HIV therapies in developing nations. The therapies include elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral (ARV) boosting agent; and the &#8220;Quad,&#8221; a once-daily combination pill of elvitegravir, cobicistat and Gilead’s another HIV combination medicine Truvada (Emtriva+Viread). The rights are an extension of the non-exclusive license granted to Matrix to produce and sell active pharmaceutical ingredients and finished products, including generic versions of Viread and Truvada in 95 developing countries including India. The license has now been expanded to include 16 additional countries, the three investigational medicines and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Expands HIV Drug&#8217;s Reach</title>
		<link>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060</link>
		<comments>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:41:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78060</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir sulfate). The deal allows Matrix to develop and sell the generic version of the HIV therapy in the Indian and sub-Saharan African markets. Apart from Reyataz, Mylan will also sell the generic versions of other Bristol-Myers HIV therapies such as Videx (didanosine) and Zerit (stavudine) in the above territories as per the agreement. The transaction marks the fifteenth deal signed by Bristol-Myers in the field of HIV and the fourth deal involving Reyataz. The deal also promises the pediatric versions of the HIV therapies. The deal permits Mylan’s Matrix Laboratories to secure prequalification from the World Health Organization (WHO) for all the offerings covered by the deal. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute</title>
		<link>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026</link>
		<comments>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:58:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77026</guid>
		<description><![CDATA[Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable conduct defense will commence on July 11, 2011. The remaining issues will be tried from September 7, 2011. Teva is challenging Mylan’s application for making a generic version of Teva&#8217;s Copaxone, a top selling drug for the treatment of multiple sclerosis. Copaxone loses patent protection in 2014. In December 2010 Teva filed a Citizen Petition (CP) with the FDA asking the agency to refuse approval to generic versions of Copaxone. The company said that any generic version of Copaxone should be subject to pre-clinical studies as well as full-scale ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362</link>
		<comments>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362#comments</comments>
		<pubDate>Mon, 30 May 2011 15:24:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74362</guid>
		<description><![CDATA[We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP) with a target price of $44.00. Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare solutions company. The company, which operates in the US, reports results through three segments: Branded Pharmaceuticals, Generics and Devices and Services. Endo Pharma offers more than 175 products in the areas of pain management, urology and oncology. In April 2011, Endo Pharma reported its first quarter 2011 results. First quarter adjusted earnings of $1.00 per share were in line with the Zacks Consensus Estimate but $0.26 above the year ago figure. The year-over-year rise in earnings was attributable to the higher revenues reported in the first quarter of 2011. We note that Endo Pharma is on an acquisition spree ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDCO) The Medicines Company Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058</link>
		<comments>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058#comments</comments>
		<pubDate>Fri, 27 May 2011 13:41:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Gbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75058</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation on The Medicines Company (MDCO), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents. Performance was boosted by higher revenues. Revenues, up 9.8% at $112.1 million, surpassed the Zacks Consensus Estimate of $110 million. The Medicines Company’s lead product, Angiomax (bivalirudin), is a specific and reversible direct thrombin inhibitor that was launched in early 2001. Despite the challenging economic scenario which has led to hospitals and patients cutting down on costly procedures, Angiomax sales in the first quarter of 2011 were up 9.7% year over year in the US. The Medicines Company received a major boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/mdco-the-medicines-company-analyst-reiterates-neutral-on-shares/75058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches New Generic Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053</link>
		<comments>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053#comments</comments>
		<pubDate>Fri, 27 May 2011 13:40:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75053</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health. We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT) Depakote Sprinkle Capsules for treating seizures. The product recorded sales of $89 million in US for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches Generic Drugs</title>
		<link>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321</link>
		<comments>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321#comments</comments>
		<pubDate>Sat, 21 May 2011 13:54:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74321</guid>
		<description><![CDATA[MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The branded product recorded sales of $116 million in US for the twelve months ending on March 31, 2011. Mylan also recently announced launches of generic versions of Cephalon’s (CEPH) Amrix which is a muscle relaxant and Johnson &#38; Johnson’s (JNJ) Risperdal which is used for the treatment of schizophrenia. As of May 16, 2011, the company had 169 abbreviated new drug applications (ANDAs) pending US Food and Drug Administration (FDA) approval targeting $100.7 billion in branded sales. Mylan believes that about 45 of the pending ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Meets Analyst Estimates &#8211; Sales Upbeat</title>
		<link>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045</link>
		<comments>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73045</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North America to deliver in line earnings growth. Earnings were nevertheless 22% above year-ago earnings of 36 cents per share. Quarter in Details Total revenues at Mylan climbed 12.1% over the prior year to $1.45 billion driven by increased sales of generic drugs. Revenue was also barely above the Zacks Consensus Estimate of $1.44 billion. Total revenues comprises both net revenues and other revenues from third parties. Mylan reports revenues from two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Drug Vandetanib Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/04/09/azn-astrazeneca-drug-vandetanib-earns-fda-approval/70911</link>
		<comments>http://www.stockbloghub.com/2011/04/09/azn-astrazeneca-drug-vandetanib-earns-fda-approval/70911#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:21:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70911</guid>
		<description><![CDATA[AstraZeneca (AZN) recently gained US Food and Drug Administration (FDA) approval for its orphan drug vandetanib for the treatment of non-operable (unresectable) locally advanced or metastatic medullary thyroid cancer (MTC). The approval, however, comes with a boxed warning and a Risk Evaluation and Mitigation Strategy (REMS). The boxed warning relates to QT prolongation, Torsades de pointes, and sudden death. Vandetanib’s approval was based on encouraging phase III data which showed that treatment with vandetanib resulted in a 65% reduction in the rate of disease progression compared to placebo. In addition to achieving the primary endpoint of progression-free survival, vandetanib also showed improvement compared to placebo in the secondary endpoints, which were objective response rate and disease control rate. The randomized, double-blind, placebo-controlled, multi-center study ZETA was conducted with 331 patients ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/azn-astrazeneca-drug-vandetanib-earns-fda-approval/70911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247</link>
		<comments>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247#comments</comments>
		<pubDate>Mon, 21 Mar 2011 03:26:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=69247</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results. Mylan’s fourth quarter 2010 earnings (excluding special items) of 45 cents per share were at par with the Zacks Consensus Estimate. Higher operating expenses offset the increase in revenue to deliver in line earnings growth. Earnings were however well above the year-ago figure of 33 cents per share. Revenues climbed 6% to $1.43 billion but fell short of the Zacks Consensus Estimate of $1.46 billion. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 5.5% to $1.35 billion in the final quarter of 2010 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Stock Market News for Dec 15, 2010 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397</link>
		<comments>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397#comments</comments>
		<pubDate>Wed, 15 Dec 2010 21:04:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abercrombie & Fitch Company]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[ANF]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BBY]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Best Buy Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62397</guid>
		<description><![CDATA[On Tuesday, the markets closed almost flat after a muted view from the Federal Reserve about the economic recovery. However, stocks were helped marginally by the positive report on retail spending. The Dow Jones Industrial Average rose 0.4% to 11,476.54.The Standard &#38; Poor&#8217;s 500 was up 0.1% to 1,241.59.The Nasdaq Composite gained 0.1% to 2,627.72. On the New York Stock Exchange, breadth of the market was negatively biased as for every 17 stocks that fell, 13 stocks ended in the green with a consolidated volume of 957 million shares. The Federal Reserve sketched out a cautious outlook of the economy in its last scheduled meeting of the year. The Fed stated that the economic recovery has not been strong enough to reduce the unemployment rate. The Federal Reserve also said ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/15/amgn-stock-market-news-for-dec-15-2010-market-news/62397/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Beats The Street on Earnings</title>
		<link>http://www.stockbloghub.com/2010/11/15/teva-teva-pharmaceutical-industries-beats-the-street-on-earnings/58457</link>
		<comments>http://www.stockbloghub.com/2010/11/15/teva-teva-pharmaceutical-industries-beats-the-street-on-earnings/58457#comments</comments>
		<pubDate>Mon, 15 Nov 2010 19:00:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58457</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) third quarter earnings of $1.30 per American Depository Share (ADS) were above the Zacks Consensus Estimate of $1.27 and the year-ago earnings of 89 cents. Teva’s top-line performance remained strong with revenues increasing 19.7% to $4.3 billion, in-line with the Zacks Consensus Estimate. Contribution from the ratiopharm acquisition, strong sales of Copaxone and generics boosted revenues and helped offset the negative impact of currency fluctuations that hit revenues by $122 million. The Quarter in Detail Revenue performance across key business segments was strong. While Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments, the Active Pharmaceutical Ingredients (API) segment posted sales of $159 million, up 17%. Pharmaceutical segment revenues were driven by strong performances in the North American, European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/teva-teva-pharmaceutical-industries-beats-the-street-on-earnings/58457/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Industry Outlook &#8211; November 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687</link>
		<comments>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687#comments</comments>
		<pubDate>Mon, 15 Nov 2010 18:56:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[KG]]></category>
		<category><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58687</guid>
		<description><![CDATA[With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. According to IMS Health, these products generated more than $17 billion ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/jnj-pharma-biotech-industry-outlook-november-2010-industry-outlook/58687/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Reports Very Strong Quarterly Earnings</title>
		<link>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105</link>
		<comments>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105#comments</comments>
		<pubDate>Mon, 01 Nov 2010 14:16:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57105</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) delivered another strong quarter with earnings coming at $2.14 per share, easily beating the Zacks Consensus Estimate of $1.79 and well above the year-ago earnings of $1.62. Strong revenues, a favorable product mix and the company’s continuing efforts to improve operating leverage helped Cephalon post impressive results. Revenues increased 30.5% to $716.9 million. However, revenues fell short of the Zacks Consensus Estimate of $719 million. The Quarter in Detail Third quarter revenues consisted of $707.1 million in product sales (up 32%) and $9.9 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $354.3 million (up 19%) and $132.9 million (up 60%), respectively. Revenues were also boosted by other product sales of $88.8 million, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/01/ceph-cephalon-reports-very-strong-quarterly-earnings/57105/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Drug ProAmatine&#8217;s Approval to be Withdrawn by US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619</link>
		<comments>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:28:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48619</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently announced that it plans to withdraw the approval of Shire plc’s (SHPGY) ProAmatine. The drug is used to treat low blood pressure (orthostatic hypotension). The drug was approved under the FDA’s accelerated approval program, under which companies are required to conduct post-approval studies of the drug in order to confirm its benefits. The regulatory body noted that since the time of the approval of ProAmatine, neither Shire nor the drug’s generic makers conducted studies that proved the drug’s efficacy in patients suffering from orthostatic hypotension. Shire, in response, issued a press release saying that it had conducted post-approval trials for ProAmatine as required by the FDA, but the regulatory body found those studies inconclusive asking Shire to carry out additional trials to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Files Lawsuit Against Apotex &#8211; Several Companies Challenging Nuvigil Patent</title>
		<link>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718</link>
		<comments>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718#comments</comments>
		<pubDate>Sat, 21 Aug 2010 18:28:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[EnergySolutions Inc]]></category>
		<category><![CDATA[ES]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48718</guid>
		<description><![CDATA[In a recent filing with the US Securities and Exchange Commission (SEC), Cephalon Inc. (CEPH) announced that it has filed a lawsuit in the US District Court in Delaware against Apotex Corp. and Apotex Inc. Apotex is seeking to launch a generic version of Cephalon’s sleep franchise product, Nuvigil. The lawsuit was filed in response to a Paragraph IV Certification Notice Letter received by Cephalon in July regarding an Abbreviated New Drug Application (ANDA) filed with the US Food and Drug Administration (FDA) by Apotex. The lawsuit has been filed under the provisions of the Hatch-Waxman Act, which means that the FDA cannot grant final approval for up to 30 months or until final resolution of the matter before the court, whichever occurs earlier. Several Companies Challenging Nuvigil Patent We ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/21/ceph-cephalon-files-lawsuit-against-apotex-several-companies-challenging-nuvigil-patent/48718/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093</link>
		<comments>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:55:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45093</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44 per share. We note that the Zacks Consensus Estimate had been revised recently following Cephalon’s announcement that it expects to deliver second quarter earnings above its previously issued guidance. Strong revenues helped the company post impressive results. Revenue increased 32.7% to $726.9 million, exceeding the Zacks Consensus Estimate by almost $19 million. The Mepha acquisition contributed $90 million to second-quarter revenue. The Quarter in Detail Second-quarter revenue consisted of $712.4 million in product sales (up 32.2%) and $14.5 million in other revenue. Revenue was driven by contributions from the central nervous system (CNS) and oncology franchises, which posted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Second Quarter 2010 Earnings Tops Estimates</title>
		<link>http://www.stockbloghub.com/2010/07/28/teva-teva-pharmaceutical-industries-second-quarter-2010-earnings-tops-estimates/45009</link>
		<comments>http://www.stockbloghub.com/2010/07/28/teva-teva-pharmaceutical-industries-second-quarter-2010-earnings-tops-estimates/45009#comments</comments>
		<pubDate>Wed, 28 Jul 2010 14:36:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45009</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) second quarter earnings of $1.08 per American Depository Share (ADS) was above the Zacks Consensus Estimate of $1.04 and the year-ago earnings of 83 cents. Teva’s top-line performance remained strong with revenues increasing 11.8% to $3.8 billion, in-line with the Zacks Consensus Estimate. Strong sales of Copaxone and generics helped drive revenues. Quarterly Details Revenue performance across key business segments was strong. While Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments, the active pharmaceutical ingredients (API) segment posted sales of $135 million, up 21%. Pharmaceutical segment revenues were driven by strong performances in the North American, European and International segments. The launch of generic versions of Hyzaar, Cozaar and Yaz and continued strong sales from existing products like ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/teva-teva-pharmaceutical-industries-second-quarter-2010-earnings-tops-estimates/45009/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914</link>
		<comments>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914#comments</comments>
		<pubDate>Tue, 27 Jul 2010 13:28:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44914</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) is scheduled to report second quarter results on July 27, 2010 after the market closes. The current Zacks Consensus Estimate for the second quarter is $1.99 per diluted share, representing year-over-year growth of 38%. Cephalon has consistently surpassed earnings estimates with a four-quarter average of 10.1%, and second quarter earnings are also expected to top expectations by 4.5%. Last week, Cephalon revised its guidance for the quarter saying that it now expects basic adjusted income per common share in the range of $2.17-$2.22 on sales of $705million-$715 million. Earlier, Cephalon was expecting basic adjusted income of $1.65-$1.75 per share on net sales of $645 &#8211; $670 million. The Zacks Consensus Revenue Estimate is $708 million. Based on the revised expectations for the second quarter, Cephalon will also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/27/ceph-cephalon-second-quarter-2010-earnings-preview/44914/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Settles Patent Fight</title>
		<link>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919</link>
		<comments>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919#comments</comments>
		<pubDate>Mon, 26 Jul 2010 21:35:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44919</guid>
		<description><![CDATA[Forest Laboratories Inc. (FRX) and partner Merz GmbH &#38; Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their generic versions of Alzheimer&#8217;s drug Namenda (memantine). As per the settlement agreement, the generic version of the drug will enter the market on January 11, 2015, three months before the patent expires in April 2010. This settlement agreement is subject to review by the US government. While Forest Labs and Merz settled the litigation with Watson Pharmaceuticals Inc. (WPI), Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Mylan Inc. (MYL), Teva Pharmaceutical Industries Ltd. (TEVA) and a few other companies, the dispute is still ongoing with certain other generic manufacturers. We believe Forest Labs and Merz will seek to settle with these companies as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/frx-forest-laboratories-settles-patent-fight/44919/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval for Generic Version of Valtrex</title>
		<link>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900</link>
		<comments>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900#comments</comments>
		<pubDate>Sun, 30 May 2010 17:11:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38900</guid>
		<description><![CDATA[Recently, Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline’s (GSK) Valtrex, a treatment for herpes virus infection. The drug recorded US sales of about $2.15 billion in 2009 for the twelve months ending March 2010. Apart from Mylan, Teva Pharmaceuticals (TEVA), Watson Pharma (WPI) and Sandoz, the generic arm of Novartis (NVS) have also received approval. Following the approval of Valtrex, Mylan’s generic portfolio will become stronger. In the past few months, Mylan has received many significant approvals. These include the generic versions of Glaxo’s smoking cessation aid, Zyban; Boehringer Ingelheim&#8217;s benign prostatic hyperplasia (BPH) treatment, Flomax and Lundbeck’s Desoxyn. Mylan received a significant approval in the field of HIV treatment for its subsidiary, Matrix. The company has received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan First Quarter 2010 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661</link>
		<comments>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661#comments</comments>
		<pubDate>Mon, 24 May 2010 21:27:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37661</guid>
		<description><![CDATA[First Quarter Highlights On April 29, Mylan (MYL) reported first quarter fiscal 2010 earnings per share (EPS) of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of 33 cents. Revenues increased 7% to $1.29 billion, mainly due to a positive foreign exchange (FX) impact. Excluding the favorable FX impact, revenues would have increased 2%. Mylan reiterated its guidance for 2010. The EPS is expected in the range of $1.50 to $1.70 and the company expects to generate total revenues of $5.45 to $5.75 billion. Agreement of Analysts Following the release of first quarter results, estimate revision trends among the analysts depict ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Reports Earnings That Beat The Street</title>
		<link>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982</link>
		<comments>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982#comments</comments>
		<pubDate>Wed, 12 May 2010 21:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36982</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) first quarter earnings of 91 cents per American Depository Share (ADS) was well above the Zacks Consensus Estimate of 89 cents and the year-ago earnings of 71 cents. Teva’s top-line performance remained strong with revenues increasing 16% to $3.7 billion. Strong sales of Copaxone and generics helped drive revenues. The Quarter in Detail Revenue performance across key business segments was mixed. While the Pharmaceuticals segment performed well thanks to strong performances in the North American, European and international segments, the Active Pharmaceutical Ingredients (API) segment reported a 13.7% decline in growth with sales coming in at $139 million. Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments. The launch of a generic version of Mirapex and continued strong sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan&#8217;s Quarterly Earnings Tops Expectations</title>
		<link>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671</link>
		<comments>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671#comments</comments>
		<pubDate>Fri, 30 Apr 2010 00:15:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35671</guid>
		<description><![CDATA[Mylan (MYL) reported first quarter earnings per share of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter 2010 earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of 33 cents. Revenues increased 7% to $1.29 billion, mainly due to a positive foreign exchange (FX) impact. Excluding the favorable FX impact, revenues would have increased 2% to $20.6 million. Both revenue segments at Mylan recorded growth during the first quarter. While Generics accounted for about 96% of total first quarter revenues, posting sales of $1.24 billion (up 7.8%), revenues from the Specialty segment increased 20.7% to $101 million. Specialty revenues were driven by higher sales of Dey&#8217;s EpiPen Auto-Injector, Perforomist Solution, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma &amp; Biotech Stock Review &#8211; April 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472</link>
		<comments>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:10:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MIL]]></category>
		<category><![CDATA[Millipore Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OSI Pharmaceuticals Inc]]></category>
		<category><![CDATA[OSIP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35472</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/abt-pharma-biotech-stock-review-april-2010-industry-outlook/35472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Completes Aquisition of Generic Drug Company Mepha AG</title>
		<link>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501</link>
		<comments>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501#comments</comments>
		<pubDate>Tue, 13 Apr 2010 03:39:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33501</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) recently announced the completion of its acquisition of Mepha AG, a privately-held Swiss generic drug company, for CHF 662.4 million (approximately $615.4 million). This acquisition marks Cephalon’s entry in the generics market. This deal is in-line with Cephalon’s goal to reduce its dependence on its central nervous system (CNS) franchise for long-term growth. The company’s CNS franchise, which consists of Nuvigil, Provigil and Gabitril, is its primary growth driver. However, Provigil is slated to face generic competition from 2012 and Nuvigil is facing patent challenges from generic players like Teva (TEVA) and Mylan (MYL). As such, Cephalon is looking to supplement long-term growth by acquiring/in-licensing products. The Mepha acquisition will not only allow Cephalon to enter the generic drug market, it will also allow the company to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/12/ceph-cephalon-completes-aquisition-of-generic-drug-company-mepha-ag/33501/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval For Laxative Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214</link>
		<comments>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214#comments</comments>
		<pubDate>Thu, 08 Apr 2010 21:19:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33214</guid>
		<description><![CDATA[Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for the generic version of Braintree Laboratories&#8217; NuLytely, a laxative. The company is eligible to ship the product immediately, which recorded US sales of about $31 million in 2009. Following this approval, Mylan’s generic portfolio will be strengthened further. We are also happy to note that in March 2010, the company had entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs &#8212; Actoplus Met and Actos &#8212; which recorded 2009 sales of $459 million and $3.4 billion, respectively. Mylan has received quite a few significant approvals in 2009 including the generic version of Bristol-Myers Squibb&#8217;s (BMY) Sinemet for treating Parkinson’s and Takeda Pharmaceuticals&#8217; proton pump inhibitor Prevacid delayed-release (DR) capsules. The company has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

